Genor Biopharma Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Genor Biopharma Holdings şirketinin toplam hissedar öz sermayesi CN¥1.1B ve toplam borcu CN¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥1.3B ve CN¥211.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

CN¥0

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥1.03b
Eşitlik	CN¥1.06b
Toplam yükümlülükler	CN¥210.98m
Toplam varlıklar	CN¥1.27b

Son finansal sağlık güncellemeleri

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

May 29

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

Dec 29

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Dec 21

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Sep 05

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Dec 03

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Aug 28

Recent updates

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Jun 20

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

May 29

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

Dec 29

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Dec 21

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Sep 05

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Dec 03

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Aug 28

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

May 10

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 6998 'nin kısa vadeli varlıkları ( CN¥1.1B ) kısa vadeli yükümlülüklerini ( CN¥189.6M ) aşıyor.

Uzun Vadeli Yükümlülükler: 6998 şirketinin kısa vadeli varlıkları ( CN¥1.1B ) uzun vadeli yükümlülüklerini ( CN¥21.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 6998 borçsuzdur.

Borcun Azaltılması: 6998 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 6998 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 6998 serbest nakit akışı her yıl % 1.4 2.1 yıl yetecek nakit akışına sahip olacaktır.

Genor Biopharma Holdings Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Recent updates

Edding Group Company Limited agreed to acquire Genor Biopharma Holdings Limited (SEHK:6998).

Genor Biopharma Holdings Limited Appoints Cui Bai as Independent Non-Executive Director and Member of the Audit Committee of the Board

Genor Biopharma Holdings Limited Announces Resignation of Zhou Honghao as Independent Non-Executive Director and Member of the Audit Committee

Genor Biopharma Holdings Limited Appoints Weng Chengyi as Chief Financial Officer

Genor Biopharma Holdings Limited Announces Directorate Changes

New minor risk - Shareholder dilution

Genor Biopharma Holdings Limited to Report First Half, 2024 Results on Aug 28, 2024

Genor Biopharma Holdings Limited's (HKG:6998) CEO Compensation Is Looking A Bit Stretched At The Moment

Here's Why We're Watching Genor Biopharma Holdings' (HKG:6998) Cash Burn Situation

Genor Biopharma Holdings Limited, Annual General Meeting, Jun 27, 2024

Genor Biopharma Holdings Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Genor Biopharma Holdings Limited Announces China National Medical Products Administration Accepts New Drug Application for GB491 (Lerociclib)

New minor risk - Share price stability

Genor Biopharma Holdings Limited Announces Board Changes

We Think Genor Biopharma Holdings (HKG:6998) Needs To Drive Business Growth Carefully

First half 2023 earnings released: CN¥0.54 loss per share (vs CN¥0.81 loss in 1H 2022)

Genor Biopharma Holdings Limited to Report First Half, 2023 Results on Aug 30, 2023

New minor risk - Market cap size

Genor Biopharma Holdings Limited Announces Updates on New Product Application Approval of Geptanolimab (GB226) for the Treatment of Relapsed/Refractory Permitting T-Cell Lymphoma

We're Hopeful That Genor Biopharma Holdings (HKG:6998) Will Use Its Cash Wisely

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Launch of Phase I/II Clinical Trial of GB263T in China

Genor Biopharma Holdings Limited Announces Launch of Phase I/Ii Clinical Trial Ofgb261 in China

Is Genor Biopharma Holdings (HKG:6998) In A Good Position To Deliver On Growth Plans?

Genor Biopharma Holdings Limited to Report First Half, 2022 Results on Aug 30, 2022

Genor Biopharma Holdings Limited Announces Management Changes with Effect from July 29, 2022

Genor Biopharma Holdings Limited Announces Executive Changes

Genor Biopharma Holdings Limited Obtains Investigational New Drug Approval from the National Medical Products Administration

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Approval for Phase I/II Clinical Trials of GB261

Genor Biopharma Holdings Limited Announces First Patient Dosed in the First-In-Humanclinical Trial of GB263T

Less than half of directors are independent

Genor Biopharma Holdings Limited Announces Resignation of Zhou Joe Xin Hua as Executive Director and President

Genor Biopharma Holdings Limited Announces First-In-Human Clinical Trial of GB263T Approval by the Bellberry Human Research Ethics Committee

Genor Biopharma Holdings Limited Announces National Medical Products Administration Grants New Drug Application Approval for GB242 (Infliximab)

We Think Genor Biopharma Holdings (HKG:6998) Can Afford To Drive Business Growth

Genor Biopharma Holdings Limited Announces First Patient Enrolled in the Phase III Clinical Trial of Gb491 in China

Here's Why We're Not Too Worried About JHBP (CY) Holdings' (HKG:6998) Cash Burn Situation

Consensus forecasts updated

JHBP (CY) Holdings Limited Receives Investigational New Drug Approval for GB492 by National Medical Products Administration

Is JHBP (CY) Holdings (HKG:6998) In A Good Position To Invest In Growth?

Non-Executive Director has left the company

Full year 2020 earnings released: CN¥12.36 loss per share (vs CN¥0.94 loss in FY 2019)

JHBP (CY) Holdings Limited Submits a Clinical Trial Application to the Bellberry Human Research Ethics Committee in Australia

JHBP (CY) Holdings Limited to Report Fiscal Year 2020 Results on Mar 23, 2021

JHBP (Cy) Holdings Limited Receives Drug Approvals from the National Medical Products Administration

JHBP (CY) Holdings Limited Appoints Han Shuhua as New Chief Scientist

New 90-day high: HK$23.00

JHBP (CY) Holdings Limited has completed an IPO in the amount of HKD 2.877144 billion.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin